TY - JOUR
T1 - Consensus recommendations by the asian pacific society of cardiology
T2 - Optimising cardiovascular outcomes in patients with type 2 diabetes
AU - Tan, Jack Wei Chieh
AU - Sim, David
AU - Ako, Junya
AU - Almahmeed, Wael
AU - Cooper, Mark E.
AU - Dalal, Jamshed J.
AU - Deerochanawong, Chaicharn
AU - Huang, David Wei Chun
AU - Johar, Sofian
AU - Kaul, Upendra
AU - Kim, Sin Gon
AU - Koh, Natalie
AU - Kong, Alice Pik Shan
AU - Krittayaphong, Rungroj
AU - Kwok, Bernard
AU - Matawaran, Bien J.
AU - Nguyen, Quang Ngoc
AU - Ong, Loke Meng
AU - Park, Jin Joo
AU - Peng, Yongde
AU - Quek, David K.L.
AU - Suastika, Ketut
AU - Sukor, Norlela
AU - Teo, Boon Wee
AU - Teoh, Chee Kiang
AU - Zhang, Jian
AU - Reyes, Eugenio B.
AU - Goh, Su Yen
N1 - Funding Information:
Disclosure: This work was funded through the Asian Pacific Society of Cardiology, with unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. JWCT reports honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AZ, Roche, Otsuka, Terumo and Abbott Vascular; and consulting fees from Elixir and CSL Behring. DS reports honoraria from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Menarini, Merck, Novartis, Otsuka, Pfizer, Roche and Servier. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi, and grants/grants pending from Daiichi Sankyo. MEC reports honoraria, speaking fees or grants from MSD/ Merck, Novo Nordisk, AstraZeneca, Boehringer-Ingelheim, Lilly, Bayer, Servier, Novartis and MundiPharma. JJD reports honoraria from Bayer and Pfizer. SJ reports honoraria from Biosense Webster and Medtronic. DKQ reports honoraria from AstraZeneca and Boehringer Ingelheim. BJM reports honoraria and CME grants from AstraZeneca, Boehringer Ingelheim, Lilly-Zuellig, MSD, Novartis, Novo Nordisk, Upjohn-Pfizer, Sanofi, and Servier. CKT reports honoraria from AstraZeneca, Boehringer Ingelheim, Novartis and Johnson & Johnson. SGK reports consulting/lecture fees or research grants from AstraZeneca, Boehringer Ingelheim, MSD, Pfizer, Takeda, Sanofi, Novo Nordisk, Novartis and Abbott. CD reports honoraria from AstraZeneca, Abbott, Bayor, Boehringer, Pfizer and Sanofi Aventis. BWT reports honoraria and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim and Otsuka. APSK reports honoraria from Abbott, AstraZeneca, Bayer, Eli Lilly and Company, Merck Serono, Nestle, Novo Nordisk, Pfizer and Sanofi. EBR reports consulting fees and speaker’s honoraria from Corbridge, Boehringer Ingelheim, E Merck, Torrent, Innogen and Servier, and research grants from MSD, Novartis and Pfizer. SYG reports advisory board honoraria from AstraZeneca, Boehringer Ingelheim, Bayer, Novo Nordisk and Sanofi. All other authors have no conflicts of interest to declare. Acknowledgement: Medical writing support was provided by Aizel Ebron and Ivan Olegario of MIMS Pte Ltd. Received: 23 December 2020 Accepted: 15 February 2021 Citation: European Cardiology Review 2021;16:e14. DOI: https://doi.org/10.15420/ecr.2020.52 Correspondence: Jack Wei Chieh Tan, National Heart Centre, 5 Hospital Dr, Singapore 169609. E: [email protected] Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
Publisher Copyright:
© RADCLIFFE CARDIOLOGY 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - The Asian Pacific Society of Cardiology convened a consensus statement panel for optimising cardiovascular (CV) outcomes in type 2 diabetes, and reviewed the current literature. Relevant articles were appraised using the Grading of Recommendations, Assessment, Development and Evaluation system, and consensus statements were developed in two meetings and were confirmed through online voting. The consensus statements indicated that lifestyle interventions must be emphasised for patients with prediabetes, and optimal glucose control should be encouraged when possible. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for patients with chronic kidney disease with adequate renal function, and for patients with heart failure with reduced ejection fraction. In addition to SGLT2i, glucagon-like peptide-1 receptor agonists are recommended for patients at high risk of CV events. A blood pressure target below 140/90 mmHg is generally recommended for patients with type 2 diabetes. Antiplatelet therapy is recommended for secondary prevention in patients with atherosclerotic CV disease.
AB - The Asian Pacific Society of Cardiology convened a consensus statement panel for optimising cardiovascular (CV) outcomes in type 2 diabetes, and reviewed the current literature. Relevant articles were appraised using the Grading of Recommendations, Assessment, Development and Evaluation system, and consensus statements were developed in two meetings and were confirmed through online voting. The consensus statements indicated that lifestyle interventions must be emphasised for patients with prediabetes, and optimal glucose control should be encouraged when possible. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for patients with chronic kidney disease with adequate renal function, and for patients with heart failure with reduced ejection fraction. In addition to SGLT2i, glucagon-like peptide-1 receptor agonists are recommended for patients at high risk of CV events. A blood pressure target below 140/90 mmHg is generally recommended for patients with type 2 diabetes. Antiplatelet therapy is recommended for secondary prevention in patients with atherosclerotic CV disease.
KW - Asia Pacific
KW - Cardiovascular
KW - Consensus
KW - Glucagon-like protein 1 receptor agonist
KW - Prediabetes
KW - Sodium-glucose cotransporter 2 inhibitor
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85105579149&partnerID=8YFLogxK
U2 - 10.15420/ECR.2020.52
DO - 10.15420/ECR.2020.52
M3 - Article
C2 - 33976709
AN - SCOPUS:85105579149
SN - 1758-3756
VL - 16
JO - European Cardiology Review
JF - European Cardiology Review
M1 - e14
ER -
